Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
about
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progressionInflammatory fibroblasts in cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.How does the tumor microenvironment play a role in hepatobiliary tumors?Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action.Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
P2860
Q36413746-75FA90EA-71DA-4056-AEE5-D2490A7722F3Q38412911-BA4A4FD8-D019-45B3-93D9-AB96FC3627E7Q38635603-95BFC5C3-007E-49EA-AF6D-21D3D5791096Q38801405-E5CB6CE7-DBA5-43D3-8FB5-7FABE7F9A302Q38803437-E6F99D13-1D85-4D46-A807-07002F131314Q41127791-8884C4CC-92B0-4C36-999A-202728F1D76AQ46251347-0F4BB6C4-9FF7-41F9-AF0A-C58222092069Q52725074-8803CE65-9E0A-44F3-9027-9F2209FE18B7Q55237274-6B5089DE-337E-4F5C-A81E-EB5C242D2875Q58755253-88FB55EC-7814-4561-A4BE-023DE0553CE7
P2860
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@ast
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@en
type
label
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@ast
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@en
prefLabel
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@ast
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Sorafenib and DE605, a novel c ...... ress hepatocellular carcinoma.
@en
P2093
Huiqiang Dou
Xiufeng Jiang
Zengyao Li
P2860
P304
12340-12356
P356
10.18632/ONCOTARGET.3656
P407
P577
2015-05-01T00:00:00Z